convalescent plasma treatment - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.88 [0.69, 1.12]< 112%7 studies (7/-)84.5 %some concernserious moderatecrucial1
deaths (time to event analysis only) 0.93 [0.47, 1.85]< 10%1 study (1/-)58.2 %lownot evaluable highcrucial-
clinical deterioration 0.48 [0.28, 0.83]< 10%2 studies (2/-)99.6 %some concernnot evaluable moderateimportant-
clinical improvement 1.04 [0.80, 1.36]> 10%4 studies (4/-)62.6 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.42 [0.65, 3.10]> 10%1 study (1/-)81.1 %some concernnot evaluable moderateimportant-
death or ventilation 0.99 [0.93, 1.05]< 10%1 study (1/-)62.7 %some concernnot evaluable moderateimportant-
ventilation 0.98 [0.88, 1.08]< 10%2 studies (2/-)67.4 %some concernnot evaluable moderateimportant1
ICU admission 0.33 [0.07, 1.58]< 10%1 study (1/-)91.7 %lownot evaluable highnon important-

safety endpoints 00

serious adverse events 0.95 [0.55, 1.64]< 140%3 studies (3/-)56.7 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.